前沿生物(688221.SH):在上海等地區逐步落地艾可寧®暴露後預防的用藥試點診所
格隆匯7月8日丨前沿生物(688221.SH)在投資者互動平台表示,目前,我國年新增10-15萬HIV感染者,其中超九成為性傳播,MSM羣體(男男性行為羣體)、男女高危性行為羣體均為亟需提高相關預防意識的高危羣體,及時的PEP措施有助於減少HIV的傳播。未來,隨着高危人羣的暴露後預防意識和用藥知識提升,HIV暴露後預防用藥的市場將逐步打開。 艾可寧®作為一款長效注射類抗HIV新藥,在艾滋病預防領域具有有效阻斷、依從性好、安全性高的藥物優勢。目前,《中國艾滋病診療指南(2021年版)》為國內針對PEP用藥最為權威的指導用書之一,艾可寧®在HIV暴露後預防的細分領域被列為推薦用藥方案。 目前,公司已經上海等地區逐步落地艾可寧®暴露後預防的用藥試點診所,後續將持續結合艾可寧®在暴露後預防領域的用藥優勢進行探索與開拓。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.